ACOX2

Across TCGA pan-cancer cohorts, ACOX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACOX2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACOX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACOX2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where ACOX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.883	0.530	.001	33	view →
UCEC	OS	Median	III,IV	0.449	1.000	.010	8	view →
LSCC	OS	Tertile	II,III,IV	0.688	1.000	.020	6	view →
LUAD	DFS	Tertile	III,IV	0.471	0.993	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACOX2–CCRCC (DFS)

Open the CCRCC breakdown →